Literature DB >> 16604339

Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model.

Jarogniew J Luszczki1, Neville Ratnaraj, Philip N Patsalos, Stanislaw J Czuczwar.   

Abstract

This study examined the interaction characteristics between loreclezole (LCZ) and various conventional antiepileptic drugs (phenytoin--PHT, carbamazepine--CBZ, valproate--VPA and phenobarbital--PB) in the mouse maximal electroshock (MES)-induced seizure model using isobolographic analysis. Drug-related adverse effects were ascertained by use of the chimney test (motor impairment) and the step-through passive avoidance task (learning and retrieval). It was observed that the combination of LCZ with VPA or PB, at the fixed ratio of 1:1, was supra-additive (synergistic) and the combination of LCZ with CBZ, at all fixed ratios tested (1:3, 1:1 and 3:1), was supra-additive against electroconvulsions. The remaining combinations evaluated, i.e., LCZ with PB or VPA at fixed ratios of 1:3 and 3:1, as well as all fixed-ratio combinations between LCZ and PHT, were additive in the MES test in mice. Pharmacokinetic characterization revealed that LCZ significantly increased both free plasma and brain concentrations of CBZ and PHT, but was without effect on PB. Moreover, a bi-directional pharmacokinetic interaction between LCZ and VPA was observed in that while LCZ increased free plasma, but not total brain VPA concentrations, VPA increased the total brain, but not free plasma LCZ concentrations. Adverse-effect testing revealed that for all antiepileptic drug combinations neither motor performance nor long-term memory was altered. Of the drug combinations investigated, only that of LCZ and PB at the fixed ratio of 1:1 was not associated with any pharmacokinetic interactions, and thus it may be concluded that the supra-additive (synergistic) isobolographic interaction was pharmacodynamic in nature. Furthermore, the fact that LCZ and PB have similar mechanisms of action would suggest that drugs with similar mechanisms of action may provide rational polytherapy regimens.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16604339     DOI: 10.1007/s00210-006-0055-4

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  60 in total

1.  The problem of synergism and antagonism of combined drugs.

Authors:  S LOEWE
Journal:  Arzneimittelforschung       Date:  1953-06

2.  Ignoring pharmacokinetics may lead to isoboles misinterpretation: illustration with the norfloxacin-theophylline convulsant interaction in rats.

Authors:  Miren Cadart; Sandrine Marchand; Claudine Pariat; Serge Bouquet; William Couet
Journal:  Pharm Res       Date:  2002-02       Impact factor: 4.200

3.  Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?

Authors:  F M Besag; D J Berry; F Pool; J E Newbery; B Subel
Journal:  Epilepsia       Date:  1998-02       Impact factor: 5.864

4.  Interaction between lamotrigine and felbamate in the maximal electroshock-induced seizures in mice: an isobolographic analysis.

Authors:  Jarogniew J Luszczki; Stanislaw J Czuczwar
Journal:  Eur Neuropsychopharmacol       Date:  2005-03       Impact factor: 4.600

Review 5.  Current limitations of antiepileptic drug therapy: a conference review.

Authors:  C L P Deckers; P Genton; G J Sills; D Schmidt
Journal:  Epilepsy Res       Date:  2003-02       Impact factor: 3.045

6.  Tiagabine synergistically interacts with gabapentin in the electroconvulsive threshold test in mice.

Authors:  Jarogniew J Luszczki; Mariusz Swiader; Jolanta Parada-Turska; Stanisław J Czuczwar
Journal:  Neuropsychopharmacology       Date:  2003-10       Impact factor: 7.853

7.  Interaction of loreclezole with conventional antiepileptic drugs in amygdala-kindled rats.

Authors:  K K Borowicz; A Sawiniec; S J Czuczwar
Journal:  Eur Neuropsychopharmacol       Date:  2004-05       Impact factor: 4.600

8.  Competitive NMDA receptor antagonists enhance the antielectroshock activity of various antiepileptics.

Authors:  T Pietrasiewicz; G Czechowska; M Dziki; W A Turski; Z Kleinrok; S J Czuczwar
Journal:  Eur J Pharmacol       Date:  1993-11-30       Impact factor: 4.432

9.  Effect of gabapentin on the anticonvulsant activity of antiepileptic drugs against electroconvulsions in mice: an isobolographic analysis.

Authors:  Kinga K Borowicz; Mariusz Swiader; Jarogniew Luszczki; Stanislaw J Czuczwar
Journal:  Epilepsia       Date:  2002-09       Impact factor: 5.864

10.  Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study.

Authors:  Jarogniew J Luszczki; Stanislaw J Czuczwar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-19       Impact factor: 3.000

View more
  14 in total

1.  Biphasic characteristic of interactions between stiripentol and carbamazepine in the mouse maximal electroshock-induced seizure model: a three-dimensional isobolographic analysis.

Authors:  Jarogniew J Luszczki; Stanislaw J Czuczwar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-09-14       Impact factor: 3.000

2.  Isobolographic analysis of interaction between drugs with nonparallel dose-response relationship curves: a practical application.

Authors:  Jarogniew J Luszczki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-03-01       Impact factor: 3.000

3.  Antagonistic Pharmacological Interaction between Sirtuin Inhibitor Cambinol and Paclitaxel in Triple-Negative Breast Cancer Cell Lines: An Isobolographic Analysis.

Authors:  Anna Wawruszak; Jarogniew Luszczki; Estera Okon; Arkadiusz Czerwonka; Andrzej Stepulak
Journal:  Int J Mol Sci       Date:  2022-06-09       Impact factor: 6.208

4.  Interactions of tiagabine with ethosuximide in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis for non-parallel dose-response relationship curves.

Authors:  Jarogniew J Luszczki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-20       Impact factor: 3.000

5.  Amiloride enhances the anticonvulsant action of various antiepileptic drugs in the mouse maximal electroshock seizure model.

Authors:  Jarogniew J Luszczki; Katarzyna M Sawicka; Justyna Kozinska; Monika Dudra-Jastrzebska; Stanislaw J Czuczwar
Journal:  J Neural Transm (Vienna)       Date:  2008-11-22       Impact factor: 3.575

6.  Agmatine enhances the anticonvulsant action of phenobarbital and valproate in the mouse maximal electroshock seizure model.

Authors:  Jarogniew J Luszczki; Remigiusz Czernecki; Katarzyna Wojtal; Kinga K Borowicz; Stanislaw J Czuczwar
Journal:  J Neural Transm (Vienna)       Date:  2008-04-01       Impact factor: 3.575

7.  Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model.

Authors:  Jarogniew J Luszczki; Jim Z Wu; Grzegorz Raszewski; Stanislaw J Czuczwar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-09-05       Impact factor: 3.000

8.  Effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline on the protective action of various antiepileptic drugs in the maximal electroshock-induced seizure model: a type II isobolographic analysis.

Authors:  Marta Andres-Mach; Anna Zadrożniak; Agnieszka Haratym-Maj; Magdalena Florek-Luszczki; Grzegorz Raszewski; Lucyna Antkiewicz-Michaluk; Jarogniew J Luszczki
Journal:  J Neural Transm (Vienna)       Date:  2013-06-07       Impact factor: 3.575

9.  Proconvulsant effects of the ketogenic diet in electroshock-induced seizures in mice.

Authors:  Iwona Zarnowska; Jarogniew J Luszczki; Tomasz Zarnowski; Piotr Wlaz; Stanislaw J Czuczwar; Maciej Gasior
Journal:  Metab Brain Dis       Date:  2016-09-20       Impact factor: 3.584

10.  Interactions among Lacosamide and Second-Generation Antiepileptic Drugs in the Tonic-Clonic Seizure Model in Mice.

Authors:  Katarzyna Załuska-Ogryzek; Paweł Marzęda; Paula Wróblewska-Łuczka; Magdalena Florek-Łuszczki; Zbigniew Plewa; Hubert Bojar; Dorota Zolkowska; Jarogniew J Łuszczki
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.